Download PDF
Semin Thromb Hemost 2016; 42(05): 563-576
DOI: 10.1055/s-0036-1581102
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Safety of Switching Factor VIII Products in the Era of Evolving Concentrates: Myths and Facts

Antonio Coppola
1   Regional Reference Center for Coagulation Disorders, Federico II University Hospital Naples, Naples, Italy
,
Emiliana Marrone
1   Regional Reference Center for Coagulation Disorders, Federico II University Hospital Naples, Naples, Italy
,
Paolo Conca
1   Regional Reference Center for Coagulation Disorders, Federico II University Hospital Naples, Naples, Italy
,
Ernesto Cimino
1   Regional Reference Center for Coagulation Disorders, Federico II University Hospital Naples, Naples, Italy
,
Rosaria Mormile
1   Regional Reference Center for Coagulation Disorders, Federico II University Hospital Naples, Naples, Italy
,
Erminia Baldacci
2   Hematology, Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Rome, Italy
,
Cristina Santoro
2   Hematology, Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Rome, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
03 June 2016 (online)

    Permissions and Reprints

Abstract

Recent advances in the development of factor VIII (FVIII) concentrates offer patients with hemophilia the opportunity to switch to products considered safer or with improved properties. In some cases, product switch occurs due to side effects, convenience issues, or economic reasons affecting clinical choices. Reluctance to change FVIII concentrates is shown by patients and also by their physicians, because of concerns in particular about the risk of inhibitor development. A literature review was performed to retrieve the best evidence regarding safety issues of switching FVIII concentrate in patients with severe hemophilia A. Product switch was not associated with an increased inhibitor risk in four studies in patients during the first 50 to 75 exposure days, or in three studies reporting national switches in Canada and United Kingdom. The latter, the only available study comparing switcher and nonswitcher patients, showed an inhibitor incidence similar to that historically reported in the United Kingdom. In 16 phase III clinical trials and 6 postmarketing studies of FVIII concentrates, few de novo inhibitors were detected in previously treated patients, mostly transient and low-titer, with some additional recurrent inhibitors in patients with previous positive testing. On the whole, although rigorous controlled studies are lacking, literature data do not support increased risk of inhibitor development or other safety issues related to product switch. Therefore, in the presence of clinical needs, the advantages of switching FVIII products should not be missed because of perceived more than evidence-based challenges, in particular in this era of products with improved properties recently introduced or available in few years. Caution, however, is suggested in patients with high inhibitor risk, including in those in concomitance with surgery or intensive treatment. A careful inhibitor testing prior to and after product switch is always needed, to identify real de novo inhibitors and to gather further information in the current evolving scenario, in particular comparing switch and nonswitch patients.

Keywords

FVIII concentrates - inhibitors - hemophilia - product switch - replacement treatment - safety
 

  • References

  • 1 Srivastava A, Brewer AK, Mauser-Bunschoten EP , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (1) e1-e47
    CrossrefPubMedGoogle Scholar
  • 2 Rocino A, Coppola A, Franchini M , et al; Italian Association of Haemophilia Centres (AICE) Working Party. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 2014; 12 (4) 575-598
    PubMedGoogle Scholar
  • 3 Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012; 38 (1) 79-94
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost 2014; 40 (5) 571-576
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39 (11–12) 1160-1168
    CrossrefPubMedGoogle Scholar
  • 6 Franchini M, Lippi G. Recombinant factor VIII concentrates. Semin Thromb Hemost 2010; 36 (5) 493-497
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood 2012; 120 (4) 720-727
    CrossrefPubMedGoogle Scholar
  • 8 Santagostino E, Auerswald G, Benson G , et al. Switching treatments in haemophilia: is there a risk of inhibitor development?. Eur J Haematol 2015; 94 (4) 284-289
    CrossrefPubMedGoogle Scholar
  • 9 Lentz SR, Misgav M, Ozelo M , et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19 (5) 691-697
    CrossrefPubMedGoogle Scholar
  • 10 Mahlangu J, Powell JS, Ragni MV , et al; A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123 (3) 317-325
    CrossrefPubMedGoogle Scholar
  • 11 Lissitchkov T, Hampton K, von Depka M , et al. Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq(®) ) in adults with severe haemophilia A: efficacy and safety. Haemophilia 2015; (e-pub ahead of print). doi:10.1111/hae.12793
    PubMedGoogle Scholar
  • 12 Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M ; LEOPOLD II Study Investigators. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 2015; 13 (3) 360-369
    CrossrefPubMedGoogle Scholar
  • 13 Konkle BA, Stasyshyn O, Chowdary P , et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015; 126 (9) 1078-1085
    CrossrefPubMedGoogle Scholar
  • 14 Franchini M, Favaloro EJ, Lippi G. Newer hemostatic agents. Semin Thromb Hemost 2015; 41 (7) 802-808
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Franchini M, Makris M, Santagostino E, Coppola A, Mannucci PM. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies. Haemophilia 2012; 18 (3) e164-e172
    CrossrefPubMedGoogle Scholar
  • 16 Musso R, Santoro R, Coppola A , et al. Patient preference for needleless factor VIII reconstitution device: the Italian experience. Int J Gen Med 2010; 3: 203-208
    PubMedGoogle Scholar
  • 17 Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M. Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. Patient Prefer Adherence 2014; 8: 1713-1720
    PubMedGoogle Scholar
  • 18 Tiede A, Klamroth R, Oldenburg J. Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results. Hamostaseologie 2015; 35 (4) 364-371
    Google Scholar
  • 19 Hay CRM, Palmer BP, Chalmers EA , et al. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison. Haemophilia 2015; 21 (2) 219-226
    CrossrefPubMedGoogle Scholar
  • 20 Franchini M, Coppola A, Rocino A , et al; Italian Association of Haemophilia Centers AICE Working Group. Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey. Haemophilia 2014; 20 (2) e128-e135
    CrossrefPubMedGoogle Scholar
  • 21 Mannucci PM, Gringeri A, Santagostino E, Peyvandi F. Factor VIII inhibitor and source of replacement therapy. Blood Transfus 2012; 10 (1) 112-113
    PubMedGoogle Scholar
  • 22 Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69 (2) 115-118
    PubMedGoogle Scholar
  • 23 Rosendaal FR, Nieuwenhuis HK, van den Berg HM , et al; Dutch Hemophilia Study Group. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993; 81 (8) 2180-2186
    PubMedGoogle Scholar
  • 24 Peerlinck K, Arnout J, Di Giambattista M , et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77 (1) 80-86
    PubMedGoogle Scholar
  • 25 White GC, DiMichele D, Mertens K , et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81 (3) 462
    PubMedGoogle Scholar
  • 26 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9 (4) 418-435
    CrossrefPubMedGoogle Scholar
  • 27 Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4693-4697
    CrossrefPubMedGoogle Scholar
  • 28 Gouw SC, van der Bom JG, Ljung R , et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368 (3) 231-239
    CrossrefPubMedGoogle Scholar
  • 29 Collins PW, Palmer BP, Chalmers EA , et al; UK Haemophilia Centre Doctors' Organization. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood 2014; 124 (23) 3389-3397
    CrossrefPubMedGoogle Scholar
  • 30 Calvez T, Chambost H, Claeyssens-Donadel S , et al; FranceCoag Network. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood 2014; 124 (23) 3398-3408
    CrossrefPubMedGoogle Scholar
  • 31 Fischer K, Lassila R, Peyvandi F , et al; EUHASS participants. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 2015; 113 (5) 968-975
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Franchini M, Coppola A, Rocino A , et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013; 39 (7) 752-766
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Hay CR, Palmer B, Chalmers E , et al; United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117 (23) 6367-6370
    CrossrefPubMedGoogle Scholar
  • 34 Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4 (12) 2576-2581
    CrossrefPubMedGoogle Scholar
  • 35 Xi M, Makris M, Marcucci M, Santagostino E, Mannucci PM, Iorio A. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost 2013; 11 (9) 1655-1662
    CrossrefPubMedGoogle Scholar
  • 36 Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 2010; 16 (102) 66-70
    CrossrefPubMedGoogle Scholar
  • 37 Gouw SC, Fijnvandraat K. Identifying nongenetic risk factors for inhibitor development in severe hemophilia a. Semin Thromb Hemost 2013; 39 (7) 740-751
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Coppola A, Santoro C, Tagliaferri A, Franchini M, DI Minno G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia 2010; 16 (Suppl. 01) 13-19
    PubMedGoogle Scholar
  • 39 Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 2011; 9 (11) 2180-2192
    CrossrefPubMedGoogle Scholar
  • 40 Iorio A, Marcucci M, Makris M. Concentrate-related inhibitor risk: is a difference always real?. J Thromb Haemost 2011; 9 (11) 2176-2179
    CrossrefPubMedGoogle Scholar
  • 41 Matino D, Lillicrap D, Astermark J , et al. Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. Haemophilia 2014; 20 (2) 200-206
    CrossrefPubMedGoogle Scholar
  • 42 Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19 (2) 139-148
    CrossrefPubMedGoogle Scholar
  • 43 Rubinger M, Lillicrap D, Rivard GE , et al; Association of Hemophilia Clinic Directors of Canada. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14 (2) 281-286
    CrossrefPubMedGoogle Scholar
  • 44 Singleton E, Smith J, Kavanagh M, Nolan B, White B. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII. Thromb Haemost 2007; 98 (6) 1188-1192
    PubMedGoogle Scholar
  • 45 Bacon CL, Singleton E, Brady B , et al. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®). Haemophilia 2011; 17 (3) 407-411
    CrossrefPubMedGoogle Scholar
  • 46 Farrugia A, Castaman G, Fagnani S. Inhibitors and product choice in haemophilia: clinical opinion in Italian treaters through an elicitation. Blood Transfus 2015; 13 (Suppl. 04) S547-s549
    PubMedGoogle Scholar
  • 47 Dmoszynska A, Kuliczkowski K, Hellmann A , et al. Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A. Haemophilia 2011; 17 (3) 456-462
    CrossrefPubMedGoogle Scholar
  • 48 Klukowska A, Windyga J, Batorova A. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients. Thromb Res 2011; 127 (3) 247-253
    CrossrefPubMedGoogle Scholar
  • 49 Abshire TC, Brackmann HH, Scharrer I , et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy—International Kogenate-FS Study Group. Thromb Haemost 2000; 83 (6) 811-816
    PubMedGoogle Scholar
  • 50 Lusher JM, Lee CA, Kessler CM, Bedrosian CL ; ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9 (1) 38-49
    PubMedGoogle Scholar
  • 51 Tarantino MD, Collins PW, Hay CR , et al; RAHF-PFM Clinical Study Group. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10 (5) 428-437
    CrossrefPubMedGoogle Scholar
  • 52 Blanchette VS, Shapiro AD, Liesner RJ , et al; rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6 (8) 1319-1326
    CrossrefPubMedGoogle Scholar
  • 53 Recht M, Nemes L, Matysiak M , et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009; 15 (4) 869-880
    CrossrefPubMedGoogle Scholar
  • 54 Kulkarni R, Karim FA, Glamocanin S , et al. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013; 19 (5) 698-705
    CrossrefPubMedGoogle Scholar
  • 55 Young G, Mahlangu J, Kulkarni R , et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015; 13 (6) 967-977
    CrossrefPubMedGoogle Scholar
  • 56 Klukowska A, Szczepański T, Vdovin V, Knaub S, Jansen M, Liesner R. Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq(®) ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics. Haemophilia 2015; (e-pub ahead of print). doi:10.1111/hae.12797
    PubMedGoogle Scholar
  • 57 Ljung R, Kenet G, Mancuso ME , et al; investigators of the LEOPOLD Kids Trial. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial. Haemophilia 2015; (e-pub ahead of print). doi:10.1111/hae.12866
    PubMedGoogle Scholar
  • 58 Pollmann H, Externest D, Ganser A , et al. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 2007; 13 (2) 131-143
    CrossrefPubMedGoogle Scholar
  • 59 Delumeau JC, Ikegawa C, Yokoyama C, Haupt V. An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A. Thromb Haemost 2008; 100 (1) 32-37
    PubMedGoogle Scholar
  • 60 Musso R, Santagostino E, Faradji A , et al; KOGENATE Bayer European PMS Study Group. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2008; 99 (1) 52-58
    PubMedGoogle Scholar
  • 61 Den Uijl I, Mauser-Bunschoten EP, Roosendaal G, Schutgens R, Fischer K. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment. Haemophilia 2009; 15 (6) 1215-1218
    CrossrefPubMedGoogle Scholar
  • 62 Oldenburg J, Goudemand J, Valentino L , et al. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice. Haemophilia 2010; 16 (6) 866-877
    CrossrefPubMedGoogle Scholar
  • 63 Parra Lopez R, Nemes L, Jimenez-Yuste V , et al. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings. Thromb Haemost 2015; 114 (4) 676-684
    Article in Thieme ConnectPubMedGoogle Scholar
  • 64 Schwartz RS, Abildgaard CF, Aledort LM , et al; and the Recombinant Factor VIII Study Group. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med 1990; 323 (26) 1800-1805
    CrossrefPubMedGoogle Scholar
  • 65 White II GC, Courter S, Bray GL, Lee M, Gomperts ED ; The Recombinate Previously Treated Patient Study Group. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77 (4) 660-667
    PubMedGoogle Scholar
  • 66 Gringeri A, Tagliaferri A, Tagariello G, Morfini M, Santagostino E, Mannucci P ; ReFacto-AICE Study Group. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol 2004; 126 (3) 398-404
    CrossrefPubMedGoogle Scholar
  • 67 Coppola A, Franchini M, Makris M, Santagostino E, Di Minno G, Mannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia 2012; 18 (3) e173-e187
    CrossrefPubMedGoogle Scholar
  • 68 Ozelo M, Misgav M, Abdul Karim F , et al. Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial. Haemophilia 2015; 21 (5) e436-e439
    CrossrefPubMedGoogle Scholar
  • 69 Nolan B, Mahlangu J, Perry D , et al. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia 2016; 22 (1) 72-80
    CrossrefPubMedGoogle Scholar
  • 70 Tiede A. Half-life extended factor VIII for the treatment of hemophilia A. J Thromb Haemost 2015; 13 (Suppl. 01) S176-S179
    CrossrefPubMedGoogle Scholar
  • 71 Collins PW, Björkman S, Fischer K , et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8 (2) 269-275
    CrossrefPubMedGoogle Scholar
  • 72 Ljung R, Auerswald G, Benson G , et al. Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. Haemophilia 2013; 19 (4) 481-486
    CrossrefPubMedGoogle Scholar
  • 73 Coppola A, Di Minno MND, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150 (5) 515-528
    CrossrefPubMedGoogle Scholar
  • 74 Peyvandi F, Mannucci PM, Garagiola I , et al. Source of factor VIII replacement (plasmatic or recombinant) and incidence of inhibitory alloantibodies in previously untreated patients with severe hemophilia A: the multicenter randomized SIPPET study. Blood 2015; 126 (23) 5 (ASH Annual Meeting Abstracts)
    CrossrefPubMedGoogle Scholar
  • 75 Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D ; The KOGENATE Study Group. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia 1999; 5 (1) 9-16
    CrossrefPubMedGoogle Scholar